Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-25T01:29:51.835Z Has data issue: false hasContentIssue false
  • English
  • Français

Co-prescribing of linezolid and serotonergic agents in a general hospital setting

Published online by Cambridge University Press:  30 June 2014

C. Clarke ,
M. Finnegan ,
A. M. O’Dwyer ,
C. Mc Donald ,
B. O’Connell  and
J. Cooney
C. Clarke*
Affiliation:
Central Mental Hospital, Dundrum, Dublin, Ireland
M. Finnegan
Affiliation:
St. Patrick’s Hospital, Dublin, Ireland
A. M. O’Dwyer
Affiliation:
Department of Psychological Medicine, St. James’ Hospital, Dublin, Ireland
C. Mc Donald
Affiliation:
Department of Pharmacy, St. James’ Hospital, Dublin, Ireland
B. O’Connell
Affiliation:
Department of Clinical Microbiology, St. James’ Hospital, Dublin, Ireland
J. Cooney
Affiliation:
Department of Psychological Medicine, St. James’ Hospital, Dublin, Ireland
*
*Address for correspondence: Dr C. Clarke, Central Mental Hospital, Dundrum, Dublin 14, Ireland. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Co-prescription of linezolid and serotonergic agents (SSRIs, SNRIs, NaSSA, TCAs) can lead to serotonin syndrome, this study seeks to identify prescribing practise of these agents.

Methods

Study of all general hospital inpatients prescribed intravenous linezolid in a 3-month period, using drug charts and clinical notes.

Results

Co-prescription occurred in 20% with SSRIs most frequently concurrently used. There were no cases of serotonin syndrome. There was no evidence in clinical notes of vigilance for potential interaction.

Conclusion

Co-prescription is common; awareness of potentially serious interaction is not evident in current practice.

Keywords

Drug interactionlinezolidserotonin syndromeSSRI
Type
Short Report
Information
Irish Journal of Psychological Medicine , Volume 31 , Issue 3 , September 2014 , pp. 191 - 193
Copyright
© College of Psychiatrists of Ireland 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cantarini, MV, Painter, CJ, Hughes, AM (2004). Effect of oral linezolid on the pressor response to intravenous tyramine. British Journal of Clinical Pharmacology 58, 470–475.Google Scholar
Falagas, ME, Vardakas, KZ (2008). Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Drug Safety: An International Journal of Medical Toxicology and Drug Experience 31, 753–768.Google Scholar
Farrell, J (2007). Zyvox: summary of product characteristics (http://www.imb.ie/images/uploaded/documents/Zyvox). Accessed 21 November 2011.Google Scholar
Lawrence, KR, Adra, M, Gillman, PK (2006). Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 42, 1578–1583.Google Scholar
Pfizer Healthcare Ireland (2012). Zyvox: summary of product characteristics (http://www.medicines.ie). Accessed 21 May 2012.Google Scholar
Quinn, DK, Stern, TA (2009). Linezolid and serotonin syndrome. Primary Care Companion to the Journal of Clinical Psychiatry 11, 353–356.Google Scholar
Taylor, JJ, Wilson, JW, Estes, LL (2006). Linezolid and serotonergic drug interactions: a retrospective survey. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 43, 180–187.Google Scholar
Vardakas, KZ, Ntziora, F, Falagas, ME (2007). Linezolid: effectiveness and safety for approved and off-label indications. Expert Opinion on Pharmacotherapy 8, 2381–2400.Google Scholar